Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
This article is a list of Acacia species (sensu lato) that are known to contain psychoactive alkaloids, or are suspected of containing such alkaloids due to being psychoactive. The presence and constitution of alkaloids in nature can be highly variable, due to environmental and genetic factors.
Bussolari of the MIT Lincoln Laboratory; the aerodynamicist was Mark Drela, with his XFOIL; in 1986, the team moves to Hanscom Field; the pilot Lois McCallin; after three to four hours of heavy exercise, the body's glucose is depleted; the first test aircraft had no ailerons, to save weight, resulting in a crash; a Hellenic Air Force C-130 arrives at Heraklion International Airport on 26 March 1988; three pilots train on Crete, eating around 7000 calories per day; the flight occurs on Saturday 23 April 1988, flying at around 18 knots; a gust of wind snapped the tail boom and wing on the beach. A US production, narrated by Andrew Sachs, produced by Mark Davis, made by WGBH. Shown on Nova on 22 November 1988 14 October Junk Mail, about direct marketing, increased by the affordability of computers, with Erik Larson.
Binding of CNP to NPR-B catalyzes the synthesis of cGMP, which is responsible for mediating the anti-fibrotic effects of CNP. Fibrotic heart tissue is associated with an increase risk of ventricular dysfunction which can ultimately lead to heart failure. Thus, anti-fibrotic strategies are a promising approach in the prevention and treatment of heart failure.
==== Evolution of animal synthesis ==== Ascorbic acid is a common enzymatic cofactor in mammals used in the synthesis of collagen, as well as a powerful reducing agent capable of rapidly scavenging a number of reactive oxygen species (ROS). Given that ascorbate has these important functions, it is surprising that the ability to synthesize this molecule has not always been conserved. In fact, anthropoid primates, Cavia porcellus (guinea pigs), teleost fishes, most bats, and some passerine birds have all independently lost the ability to internally synthesize vitamin C in either the kidney or the liver. In all of the cases where genomic analysis was done on an ascorbic acid auxotroph, the origin of the change was found to be a result of loss-of-function mutations in the gene that encodes L-gulono-γ-lactone oxidase, the enzyme that catalyzes the last step of the ascorbic acid pathway outlined above. One explanation for the repeated loss of the ability to synthesize vitamin C is that it was the result of genetic drift; assuming that the diet was rich in vitamin C, natural selection would not act to preserve it.
=== Secondary glaucoma === Secondary glaucoma (H40.3-H40.6) encompasses numerous subtypes: inflammatory glaucoma (all types of uveitis, Fuchs heterochromic iridocyclitis); phacogenic glaucoma (angle-closure with mature cataract, phacoanaphylactic glaucoma from lens capsule rupture, phacolytic glaucoma, lens subluxation); glaucoma secondary to intraocular hemorrhage (hyphema, hemolytic/erythroclastic glaucoma); traumatic glaucoma (angle recession glaucoma); postsurgical glaucoma (aphakic pupillary block, ciliary block); neovascular glaucoma; drug-induced glaucoma (corticosteroid-induced, alpha-chymotrypsin); and glaucoma of miscellaneous origin (associated with intraocular tumors, retinal detachments, severe chemical burns, essential iris atrophy, or toxic glaucoma). Neovascular glaucoma, an uncommon type of glaucoma, is difficult or nearly impossible to treat, and is often caused by proliferative diabetic retinopathy (PDR) or central retinal vein occlusion (CRVO). It may also be triggered by other conditions that result in ischemia of the retina or ciliary body. Individuals with poor blood flow to the eye are highly at risk for this condition. Neovascular glaucoma results when new, abnormal vessels begin developing in the angle of the eye that begin blocking the drainage. People with such a condition begin to rapidly lose their eyesight. Sometimes, the disease appears very rapidly, especially after cataract surgery procedures. Toxic glaucoma is open-angle glaucoma with an unexplained significant rise of intraocular pressure following an unknown pathogenesis.
Sources: en.wikipedia.org
== See also == Biomaterials Bioplastic Biopolymers & Cell (journal) Condensation polymers Condensed tannins DNA sequence Food microbiology § Microbial biopolymers Melanin Non food crops Phosphoramidite Polymer chemistry Sequence-controlled polymers Sequencing Small molecules Worm-like chain
== Treatment == Treatment depends on the type and severity of the condition. The majority of the autoimmune diseases are chronic and there is no definitive cure, but symptoms can be alleviated and controlled with treatment. Standard treatment methods include:
A bone is a rigid organ that constitutes part of the skeleton in most vertebrate animals. Bones protect the organs of the body, produce red and white blood cells, store minerals, help regulate acid-base homeostasis, provide structure and support for the body, and enable mobility and hearing. Bones come in a variety of shapes and sizes and have complex internal and external structures. Bone tissue (also known as osseous tissue or bone in the uncountable) is a form of hard tissue, specialised connective tissue that is mineralized and has an intercellular honeycomb-like matrix, which helps to give the bone rigidity. Bone tissue is made up of different types of bone cells: osteoblasts and osteocytes (which form and mineralise bone respectively), osteoclasts (which resorb bone), and modified or flattened osteoblasts (lining cells that form a protective layer on the bone surface). The mineralised matrix of bone tissue has an organic component of mainly ossein, a form of collagen, and an inorganic component of bone mineral, made up of various salts. Bone tissue comprises cortical (compact) bone and cancellous (spongy) bone, although bones may also contain other kinds of tissue including bone marrow, endosteum, periosteum, nerves, blood vessels, and cartilage. In the human body at birth, approximately 300 bones are present. Many of these fuse together during development, leaving a total of 206 separate bones in the adult, not counting numerous small sesamoid bones. The largest bone in the body is the femur or thigh-bone, and the smallest is the stapes in the middle ear.
Hypertrophic scars occur when the body overproduces collagen, which causes the scar to be raised above the surrounding skin. Hypertrophic scars take the form of a red raised lump on the skin for lighter pigmented skin and the form of dark brown for darker pigmented skin. They usually occur within 4 to 8 weeks following wound infection or wound closure with excess tension and/or other traumatic skin injuries.
Collagen is the main component of the extracellular matrix (ECM). The collagen superfamily consists of 28 different types of collagen. Although the function and hierarchical structure of these collagens may vary, they all share the defining structural feature known as the triple helix, where three left handed polyproline II-type (PPII) helices assemble to form a right-handed supercoiled helical motif. Short synthetic peptides known as collagen mimetic peptides (CMPs) or collagen-like peptides (CLPs) have played a major role in elucidating the 3D structure of the collagen triple helix, its folding kinetics, and thermal stability as small triple helical models. CMPs, CLPs, and CHPs are all very similar in terms of their amino acid sequences but only when CMPs or CLPs are heated above their melting temperatures, do they exist in the dissociated, single-stranded state and can be considered as CHPs.
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.